Non-small cell lung cancers Market
Aug 23, 2019
Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario?
The drug Imfinzi (durvalumab) has failed to come up as an effective treatment option for treating non-small cell lung cancer (NSCLC). The result of the NEPTUNE study was not much of a promising one and has been disclosed completely. The Pharma giant, AstraZeneca, has announced the incompetence of its lead candidate...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
